Want to see OLMA full AI Analyst Report?
OLMA Stock Chart & Stats
$10.91
-$0.04(-0.34%)
At close: 4:00 PM EDT
$10.91
-$0.04(-0.34%)
Day’s Range― - ―
52-Week Range$6.48 - $36.26
Previous CloseN/A
Volume806.83K
Average Volume (3M)1.25M
Market Cap
$622.11M
Enterprise Value$849.31M
Total Cash (Recent Filing)$461.07M
Total Debt (Recent Filing)$660.00K
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Nov 10, 2026EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.12
Shares Outstanding87,497,604
10 Day Avg. Volume1,207,158
30 Day Avg. Volume1,245,047
Financial Highlights & Ratios
PEG Ratio0.89
Price to Book (P/B)4.55
Price to Sales (P/S)0.00
P/FCF Ratio-14.83
Enterprise Value/Market Cap1.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.78K
Enterprise Value/Ebitda-4.16
Forecast
1Y Price Target
$33.17Price Target Upside204.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.39
Revenue Forecast (FY)$2.25M
Bulls Say, Bears Say
Bulls Say
Low LeverageExtremely low leverage gives Olema meaningful financial flexibility while it funds clinical development. The limited debt burden reduces fixed obligations and refinancing exposure, allowing more capital to remain available for research, trials, and potential commercialization.
Late-Stage Oncology PipelineThe presence of two Phase 3 trials gives Olema more advanced clinical programs than an early discovery portfolio alone. Progress toward pivotal data and a potential first launch could create a clearer path from research spending to future commercial revenue.
Experienced Financial LeadershipHiring an experienced biotech finance executive strengthens leadership as Olema approaches pivotal data and prepares for possible commercialization. Expertise across capital markets and operating functions may support disciplined funding decisions during the transition toward an integrated oncology business.
Bears Say
No Commercial RevenueZero revenue confirms that Olema remains dependent on clinical progress rather than an established commercial product base. Until a program reaches market, operating resources must be funded without recurring product sales, leaving future revenue timing highly dependent on development outcomes.
Widening LossesThe widening loss shows that Olema’s expense base is increasing faster than its ability to generate income, consistent with continued development investment. Persistent negative profitability can consume shareholder capital and raises the financial stakes of achieving successful clinical and regulatory progress.
Sustained Cash BurnSustained and increasing cash burn means Olema needs substantial funding to maintain operations and advance its pipeline. Even with low debt, ongoing negative cash generation can reduce financial flexibility over time and increase reliance on future financing.
Olema Pharmaceuticals News
OLMA FAQ
What was Olema Pharmaceuticals’s price range in the past 12 months?
Olema Pharmaceuticals lowest stock price was $6.48 and its highest was $36.26 in the past 12 months.
What is Olema Pharmaceuticals’s market cap?
Olema Pharmaceuticals’s market cap is $622.11M.
When is Olema Pharmaceuticals’s upcoming earnings report date?
Olema Pharmaceuticals’s upcoming earnings report date is Nov 10, 2026 which is in 21 days.
How were Olema Pharmaceuticals’s earnings last quarter?
Olema Pharmaceuticals released its earnings results on Aug 10, 2026. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.551 by -$0.059.
Is Olema Pharmaceuticals overvalued?
According to Wall Street analysts Olema Pharmaceuticals’s price is currently Undervalued.
Does Olema Pharmaceuticals pay dividends?
Olema Pharmaceuticals does not currently pay dividends.
What is Olema Pharmaceuticals’s EPS estimate?
Olema Pharmaceuticals’s EPS estimate is -0.64.
How many shares outstanding does Olema Pharmaceuticals have?
Olema Pharmaceuticals has 87,497,604 shares outstanding.
What happened to Olema Pharmaceuticals’s price movement after its last earnings report?
Olema Pharmaceuticals reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.551. Following the earnings report the stock price went down -12.647%.
Which hedge fund is a major shareholder of Olema Pharmaceuticals?
Currently, no hedge funds are holding shares in OLMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Olema Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.17 (204.00% Upside)
$33.17 (204.00% Upside)
Blogger Sentiment
Bullish
OLMA Sentiment 80%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 3.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $291.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.03%
12-Months-Change
Fundamentals
Return on Equity
-48.22%
Trailing 12-Months
Asset Growth
27.38%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Olema Pharmaceuticals
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
OLMA Stock 12 Month Forecast
Average Price Target
$33.17
▲(204.00% Upside)
Technical Analysis
Meiragtx Holdings
―
Arvinas Holding Company
―
Gossamer Bio
―
Keros Therapeutics
―
Compass Therapeutics
―
Ownership Overview
10.18% Insiders
21.20% Mutual Funds
0.59% Other Institutional Investors
52.76% Public Companies and Individual Investors